Journal
CELLS TISSUES ORGANS
Volume 211, Issue 2, Pages 157-182Publisher
KARGER
DOI: 10.1159/000512218
Keywords
EMT; Therapy; Metastasis; Drug screening; Drosophila melanogaster; Zebrafish
Funding
- Strategic Basic Research (SBO) [S008518 N]
- Stand up to Cancer (Kom op tegen Kanker)
- Belgian Federation Against Cancer (BFAC)
- Welcome Trust/Royal Society Sir Henry Dale Fellowship [204615/Z/16/Z]
- Wellcome Trust [204615/Z/16/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Metastasis, the spread of cancer cells to distant sites, is the primary cause of cancer morbidity and mortality. During the initial stages of metastasis, cancer cells undergo EMT, becoming migratory and invasive mesenchymal-like cells with stem cell properties. Targeting EMT in therapy has the potential to prevent cancer cell invasion and dissemination, reduce cancer stemness, and enhance the effectiveness of chemotherapy.
Metastasis is the spread of cancer cells from the primary tumour to distant sites and organs throughout the body. It is the primary cause of cancer morbidity and mortality, and is estimated to account for 90% of cancer-related deaths. During the initial steps of the metastatic cascade, epithelial cancer cells undergo an epithelial-mesenchymal transition (EMT), and as a result become migratory and invasive mesenchymal-like cells while acquiring cancer stem cell properties and therapy resistance. As EMT is involved in such a broad range of processes associated with malignant transformation, it has become an increasingly interesting target for the development of novel therapeutic strategies. Anti-EMT therapeutic strategies could potentially not only prevent the invasion and dissemination of cancer cells, and as such prevent the formation of metastatic lesions, but also attenuate cancer stemness and increase the effectiveness of more classical chemotherapeutics. In this review, we give an overview about the pros and cons of therapies targeting EMT and discuss some already existing candidate drug targets and high-throughput screening tools to identify novel anti-EMT compounds.(c) 2021 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available